

Low Grade Serous Ovarian Carcinoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2023-2033

<https://marketpublishers.com/r/L0E3D76CC684EN.html>

Date: October 2023

Pages: 236

Price: US\$ 5,499.00 (Single User License)

ID: L0E3D76CC684EN

Abstracts

Market Overview:

The 7 major low grade serous ovarian carcinoma markets reached a value of US\$ 158.5 Million in 2022. Looking forward, IMARC Group expects the 7MM to reach US\$ 349.2 Million by 2033, exhibiting a growth rate (CAGR) of 6.9% during 2023-2033.

The low grade serous ovarian carcinoma market has been comprehensively analyzed in IMARC's new report titled 'Low Grade Serous Ovarian Carcinoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2023-2033'. Low grade serous ovarian carcinoma (LGSOC) refers to a rare subtype of epithelial ovarian cancer that grows slowly and has a relatively better prognosis compared to other types of ovarian cancer. It is characterized by the presence of small, uniform tumor cells that form glandular structures. The common symptoms of this condition include chronic stomach pain, difficulty eating, bloating, changes to bowel movements, urinary urgency, etc. Individuals suffering from LGSOC may also experience a sudden feeling of fullness, reduced appetite, and pain in the stomach, back, and pelvis. The diagnosis of the ailment typically requires a combination of clinical examination, medical history, and a pelvic test. A CA125 blood workup, which can detect a protein in the body that is a cancer marker, is further utilized for disease detection among patients. The healthcare provider may perform transvaginal ultrasound and computerized tomography scans to rule out other possible causes and confirm a diagnosis.

The rising prevalence of inherited genetic disorders, causing DNA abnormalities, gene variations, and chromosomal damage, is primarily driving the low grade serous ovarian

carcinoma market. Furthermore, the increasing incidences of various associated risk factors, such as family history, obesity, past childbirth, pregnancy, advancing age, etc., are also augmenting the market growth. Apart from this, the widespread adoption of kinase inhibitors, including pertuzumab, afatinib, trastuzumab, etc., to reduce tumor cells and block disease progression among patients is further creating a positive outlook for the market. Additionally, the emerging popularity of real-time molecular profiling technologies, since they can support the management of the underlying ailment by identifying genetic mutations and other molecular abnormalities that cause LGSOC, is also bolstering the market growth. Moreover, the inflating utilization of cytoreductive surgery and platinum-based chemotherapy which enhance host immunological response, thereby eradicating cancer masses and improving overall survival, is acting as another significant growth-inducing factor. In addition to this, the escalating demand for biomarker testing and sequencing that help in early diagnosis, predict response to therapy, and monitor disease progression is expected to drive the low grade serous ovarian carcinoma market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the low grade serous ovarian carcinoma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for low grade serous ovarian carcinoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the low grade serous ovarian carcinoma market in any manner.

Time Period of the Study

Base Year: 2022

Historical Period: 2017-2022

Market Forecast: 2023-2033

Countries Covered

United States

Germany

France

United Kingdom

Italy

Spain

Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario

Historical, current, and future performance of the low grade serous ovarian carcinoma market

Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the low grade serous ovarian carcinoma market

Reimbursement scenario in the market

In-market and pipeline drugs

This report also provides a detailed analysis of the current low grade serous ovarian carcinoma marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Key Questions Answered in this Report

Market Insights

How has the low grade serous ovarian carcinoma market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2022 and how are they expected to perform till 2033?

What was the country-wise size of the low grade serous ovarian carcinoma market across the seven major markets in 2022 and what will it look like in 2033?

What is the growth rate of the low grade serous ovarian carcinoma market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2017-2033) of low grade serous ovarian carcinoma across the seven major markets?

What is the number of prevalent cases (2017-2033) of low grade serous ovarian carcinoma by age across the seven major markets?

What is the number of prevalent cases (2017-2033) of low grade serous ovarian carcinoma by gender across the seven major markets?

How many patients are diagnosed (2017-2033) with low grade serous ovarian carcinoma across the seven major markets?

What is the size of the low grade serous ovarian carcinoma patient pool (2017-2022) across the seven major markets?

What would be the forecasted patient pool (2023-2033) across the seven major markets?

What are the key factors driving the epidemiological trend of low grade serous ovarian carcinoma?

What will be the growth rate of patients across the seven major markets?

Low Grade Serous Ovarian Carcinoma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for low grade serous ovarian carcinoma drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the low grade serous ovarian carcinoma market?

What are the key regulatory events related to the low grade serous ovarian carcinoma market?

What is the structure of clinical trial landscape by status related to the low grade serous ovarian carcinoma market?

What is the structure of clinical trial landscape by phase related to the low grade serous ovarian carcinoma market?

What is the structure of clinical trial landscape by route of administration related to the low grade serous ovarian carcinoma market?

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 LOW GRADE SEROUS OVARIAN CARCINOMA - INTRODUCTION

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2017-2022) and Forecast (2023-2033)
- 4.4 Market Overview (2017-2022) and Forecast (2023-2033)
- 4.5 Competitive Intelligence

5 LOW GRADE SEROUS OVARIAN CARCINOMA - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

6 PATIENT JOURNEY

7 LOW GRADE SEROUS OVARIAN CARCINOMA - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights
- 7.2 Epidemiology Scenario - Top 7 Markets
 - 7.2.1 Epidemiology Scenario (2017-2022)
 - 7.2.2 Epidemiology Forecast (2023-2033)
 - 7.2.3 Epidemiology by Age (2017-2033)
 - 7.2.4 Epidemiology by Gender (2017-2033)
 - 7.2.5 Diagnosed Cases (2017-2033)
 - 7.2.6 Patient Pool/Treated Cases (2017-2033)
- 7.3 Epidemiology Scenario - United States
 - 7.3.1 Epidemiology Scenario (2017-2022)
 - 7.3.2 Epidemiology Forecast (2023-2033)
 - 7.3.3 Epidemiology by Age (2017-2033)
 - 7.3.4 Epidemiology by Gender (2017-2033)
 - 7.3.5 Diagnosed Cases (2017-2033)
 - 7.3.6 Patient Pool/Treated Cases (2017-2033)
- 7.4 Epidemiology Scenario - Germany
 - 7.4.1 Epidemiology Scenario (2017-2022)
 - 7.4.2 Epidemiology Forecast (2023-2033)
 - 7.4.3 Epidemiology by Age (2017-2033)
 - 7.4.4 Epidemiology by Gender (2017-2033)
 - 7.4.5 Diagnosed Cases (2017-2033)
 - 7.4.6 Patient Pool/Treated Cases (2017-2033)
- 7.5 Epidemiology Scenario - France
 - 7.5.1 Epidemiology Scenario (2017-2022)
 - 7.5.2 Epidemiology Forecast (2023-2033)
 - 7.5.3 Epidemiology by Age (2017-2033)
 - 7.5.4 Epidemiology by Gender (2017-2033)
 - 7.5.5 Diagnosed Cases (2017-2033)
 - 7.5.6 Patient Pool/Treated Cases (2017-2033)
- 7.6 Epidemiology Scenario - United Kingdom
 - 7.6.1 Epidemiology Scenario (2017-2022)
 - 7.6.2 Epidemiology Forecast (2023-2033)
 - 7.6.3 Epidemiology by Age (2017-2033)
 - 7.6.4 Epidemiology by Gender (2017-2033)
 - 7.6.5 Diagnosed Cases (2017-2033)
 - 7.6.6 Patient Pool/Treated Cases (2017-2033)
- 7.7 Epidemiology Scenario - Italy
 - 7.7.1 Epidemiology Scenario (2017-2022)
 - 7.7.2 Epidemiology Forecast (2023-2033)

- 7.7.3 Epidemiology by Age (2017-2033)
- 7.7.4 Epidemiology by Gender (2017-2033)
- 7.7.5 Diagnosed Cases (2017-2033)
- 7.7.6 Patient Pool/Treated Cases (2017-2033)
- 7.8 Epidemiology Scenario - Spain
 - 7.8.1 Epidemiology Scenario (2017-2022)
 - 7.8.2 Epidemiology Forecast (2023-2033)
 - 7.8.3 Epidemiology by Age (2017-2033)
 - 7.8.4 Epidemiology by Gender (2017-2033)
 - 7.8.5 Diagnosed Cases (2017-2033)
 - 7.8.6 Patient Pool/Treated Cases (2017-2033)
- 7.9 Epidemiology Scenario - Japan
 - 7.9.1 Epidemiology Scenario (2017-2022)
 - 7.9.2 Epidemiology Forecast (2023-2033)
 - 7.9.3 Epidemiology by Age (2017-2033)
 - 7.9.4 Epidemiology by Gender (2017-2033)
 - 7.9.5 Diagnosed Cases (2017-2033)
 - 7.9.6 Patient Pool/Treated Cases (2017-2033)

8 LOW GRADE SEROUS OVARIAN CARCINOMA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

9 LOW GRADE SEROUS OVARIAN CARCINOMA - UNMET NEEDS

10 LOW GRADE SEROUS OVARIAN CARCINOMA - KEY ENDPOINTS OF TREATMENT

11 LOW GRADE SEROUS OVARIAN CARCINOMA - MARKETED PRODUCTS

- 11.1 List of Low Grade Serous Ovarian Carcinoma Marketed Drugs Across the Top 7 Markets
 - 11.1.1 Drug Name – Company Name
 - 11.1.1.1 Drug Overview
 - 11.1.1.2 Mechanism of Action
 - 11.1.1.3 Regulatory Status
 - 11.1.1.4 Clinical Trial Results

11.1.1.5 Sales Across Major Markets

Kindly note that the complete list of marketed drugs has been provided in the report.

12 LOW GRADE SEROUS OVARIAN CARCINOMA - PIPELINE DRUGS

12.1 List of Low Grade Serous Ovarian Carcinoma Pipeline Drugs Across the Top 7 Markets

12.1.1 MEK162 - Pfizer

12.1.1.1 Drug Overview

12.1.1.2 Mechanism of Action

12.1.1.3 Clinical Trial Results

12.1.1.4 Safety and Efficacy

12.1.1.5 Regulatory Status

12.1.2 Avutometinib - Verastem Oncology

12.1.2.1 Drug Overview

12.1.2.2 Mechanism of Action

12.1.2.3 Clinical Trial Results

12.1.2.4 Safety and Efficacy

12.1.2.5 Regulatory Status

12.1.3 Pembrolizumab - Merck & Co

12.1.3.1 Drug Overview

12.1.3.2 Mechanism of Action

12.1.3.3 Clinical Trial Results

12.1.3.4 Safety and Efficacy

12.1.3.5 Regulatory Status

12.1.4 Ribociclib/ Letrozole - Novartis

12.1.4.1 Drug Overview

12.1.4.2 Mechanism of Action

12.1.4.3 Clinical Trial Results

12.1.4.4 Safety and Efficacy

12.1.4.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report

13. LOW GRADE SEROUS OVARIAN CARCINOMA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14. LOW GRADE SEROUS OVARIAN CARCINOMA – CLINICAL TRIAL LANDSCAPE

- 14.1 Drugs by Status
- 14.2 Drugs by Phase
- 14.3 Drugs by Route of Administration
- 14.4 Key Regulatory Events

15 LOW GRADE SEROUS OVARIAN CARCINOMA - MARKET SCENARIO

- 15.1 Market Scenario - Key Insights
- 15.2 Market Scenario - Top 7 Markets
 - 15.2.1 Low Grade Serous Ovarian Carcinoma - Market Size
 - 15.2.1.1 Market Size (2017-2022)
 - 15.2.1.2 Market Forecast (2023-2033)
 - 15.2.2 Low Grade Serous Ovarian Carcinoma - Market Size by Therapies
 - 15.2.2.1 Market Size by Therapies (2017-2022)
 - 15.2.2.2 Market Forecast by Therapies (2023-2033)
- 15.3 Market Scenario - United States
 - 15.3.1 Low Grade Serous Ovarian Carcinoma - Market Size
 - 15.3.1.1 Market Size (2017-2022)
 - 15.3.1.2 Market Forecast (2023-2033)
 - 15.3.2 Low Grade Serous Ovarian Carcinoma - Market Size by Therapies
 - 15.3.2.1 Market Size by Therapies (2017-2022)
 - 15.3.2.2 Market Forecast by Therapies (2023-2033)
 - 15.3.3 Low Grade Serous Ovarian Carcinoma - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany
 - 15.4.1 Low Grade Serous Ovarian Carcinoma - Market Size
 - 15.4.1.1 Market Size (2017-2022)
 - 15.4.1.2 Market Forecast (2023-2033)
 - 15.4.2 Low Grade Serous Ovarian Carcinoma - Market Size by Therapies
 - 15.4.2.1 Market Size by Therapies (2017-2022)
 - 15.4.2.2 Market Forecast by Therapies (2023-2033)
 - 15.4.3 Low Grade Serous Ovarian Carcinoma - Access and Reimbursement Overview
- 15.5 Market Scenario - France
 - 15.5.1 Low Grade Serous Ovarian Carcinoma - Market Size
 - 15.5.1.1 Market Size (2017-2022)
 - 15.5.1.2 Market Forecast (2023-2033)
 - 15.5.2 Low Grade Serous Ovarian Carcinoma - Market Size by Therapies
 - 15.5.2.1 Market Size by Therapies (2017-2022)
 - 15.5.2.2 Market Forecast by Therapies (2023-2033)

- 15.5.3 Low Grade Serous Ovarian Carcinoma - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
 - 15.6.1 Low Grade Serous Ovarian Carcinoma - Market Size
 - 15.6.1.1 Market Size (2017-2022)
 - 15.6.1.2 Market Forecast (2023-2033)
 - 15.6.2 Low Grade Serous Ovarian Carcinoma - Market Size by Therapies
 - 15.6.2.1 Market Size by Therapies (2017-2022)
 - 15.6.2.2 Market Forecast by Therapies (2023-2033)
 - 15.6.3 Low Grade Serous Ovarian Carcinoma - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
 - 15.7.1 Low Grade Serous Ovarian Carcinoma - Market Size
 - 15.7.1.1 Market Size (2017-2022)
 - 15.7.1.2 Market Forecast (2023-2033)
 - 15.7.2 Low Grade Serous Ovarian Carcinoma - Market Size by Therapies
 - 15.7.2.1 Market Size by Therapies (2017-2022)
 - 15.7.2.2 Market Forecast by Therapies (2023-2033)
 - 15.7.3 Low Grade Serous Ovarian Carcinoma - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
 - 15.8.1 Low Grade Serous Ovarian Carcinoma - Market Size
 - 15.8.1.1 Market Size (2017-2022)
 - 15.8.1.2 Market Forecast (2023-2033)
 - 15.8.2 Low Grade Serous Ovarian Carcinoma - Market Size by Therapies
 - 15.8.2.1 Market Size by Therapies (2017-2022)
 - 15.8.2.2 Market Forecast by Therapies (2023-2033)
 - 15.8.3 Low Grade Serous Ovarian Carcinoma - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
 - 15.9.1 Low Grade Serous Ovarian Carcinoma - Market Size
 - 15.9.1.1 Market Size (2017-2022)
 - 15.9.1.2 Market Forecast (2023-2033)
 - 15.9.2 Low Grade Serous Ovarian Carcinoma - Market Size by Therapies
 - 15.9.2.1 Market Size by Therapies (2017-2022)
 - 15.9.2.2 Market Forecast by Therapies (2023-2033)
 - 15.9.3 Low Grade Serous Ovarian Carcinoma - Access and Reimbursement Overview

16 LOW GRADE SEROUS OVARIAN CARCINOMA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 LOW GRADE SEROUS OVARIAN CARCINOMA MARKET - SWOT ANALYSIS

17.1 Strengths

17.2 Weaknesses

17.3 Opportunities

17.4 Threats

18 LOW GRADE SEROUS OVARIAN CARCINOMA MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX

List Of Tables

LIST OF TABLES

List Of Figures

LIST OF FIGURES

I would like to order

Product name: Low Grade Serous Ovarian Carcinoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2023-2033

Product link: <https://marketpublishers.com/r/L0E3D76CC684EN.html>

Price: US\$ 5,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/L0E3D76CC684EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

